Weekly Digest - Feb 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Feb 2024
12 Feb 2024: AbbVie acquires ImmunoGen, including flagship ADC Elahere
- AbbVie finalized its acquisition of ImmunoGen, which bolsters the company’s pipeline of antibody-drug conjugates (ADCs)
- AbbVie gains ImmunoGen’s flagship ADC Elahere (mirvetuximab soravtansine-gynx) which has granted accelerated approval by FDA for adults with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who has received one of three systemic treatment regimens that included Avastin
- In SORAYA trial, Elahere demonstrated impressive anti-tumor activity and Results from the Phase III MIRASOL confirmatory trial will be used to support the submission of a supplemental BLA
- Beyond Elahere, ImmunoGen’s Phase I next-generation anti-FRα ADC, IMGN-151, is being evaluated for the treatment of ovarian cancer and a Phase II anti-CD123 ADC, pivekimab sunirine, which also has granted Breakthrough Therapy Designation for relapsed/refractory BPDCN
